+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rigel Pharmaceuticals Inc - logo

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.

Psoriasis (Immunology) - Drugs In Development, 2021 - Product Thumbnail Image

Psoriasis (Immunology) - Drugs In Development, 2021

  • Report
  • July 2021
  • 1178 Pages
From
From
From
From
Warm Autoimmune Hemolytic Anemia (WAIHA) - Pipeline Insight, 2020 - Product Thumbnail Image

Warm Autoimmune Hemolytic Anemia (WAIHA) - Pipeline Insight, 2020

  • Clinical Trials
  • September 2020
  • 70 Pages
From
From
From
Gouty Arthritis (Gout) - Pipeline Review, H2 2020 - Product Thumbnail Image

Gouty Arthritis (Gout) - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 139 Pages
From
From
From
From
From
Myelodysplastic Syndrome - Pipeline Insight, 2021 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Insight, 2021

  • Drug Pipelines
  • September 2021
  • 60 Pages
From
From
Psoriasis - Pipeline Review, H2 2020 - Product Thumbnail Image

Psoriasis - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 956 Pages
From
Loading Indicator